Evidence map›Paper›PMID 22927238›Full record

ArticleChemMedChem2012

Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

Julie K Furmick, Ichiro Kaneko, Angela N Walsh, Joanna Yang, Jaskaran S Bhogal, Geoffrey M Gray, Juan C Baso, Drew O Browder, Jessica L S Prentice, Luis A Montano and 13 more

Abstract read
In one paragraph

Article in ChemMedChem, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Julie K FurmickSchool of Mathematical and Natural Sciences, New College of Interdisciplinary Arts&Sciences, Arizona State University, 4701 W. Thunderbird Rd., Glendale, AZ 85306, USA.
Ichiro Kaneko
Angela N Walsh
Joanna Yang
Jaskaran S Bhogal
Geoffrey M Gray
Juan C Baso
Drew O Browder
Jessica L S Prentice
Luis A Montano
Chanh C Huynh
Lisa M Marcus
Dorian G Tsosie
Jungeun S Kwon
Alexis Quezada
Nicole M Reyes
Brittney Lemming
Puneet Saini
Arjan van der Vaart
Thomas L Groy
Pamela A Marshall
Peter W Jurutka
Carl E Wagner
Arizona State University · USUniversity of South Florida · US

Funding

Modeling, Synthesis, and Biological Evaluation of Potential RXT Selective AgonistR15CA139364 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI WAGNER, CARL EDWARD · 2011 to 2011
$458k
NCI NIH HHS 1 R15 CA139364-01A2NCI NIH HHS R15 CA139364
6 · The paper itself

Abstract

The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoid X receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE-mediated transcriptional assay as well as an RXR mammalian-2-hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR-mediated transcription with EC(50) values similar to that of 1 and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton ortho to the carboxylic acid on 1.

Indexed as

AnimalsAnticarcinogenic AgentsApoptosisBexaroteneCell Line, TumorHalogenationHumansLymphoma, T-Cell, CutaneousMolecular Docking SimulationNeoplasmsProtein MultimerizationRetinoid X ReceptorsTetrahydronaphthalenesAnticarcinogenic AgentsBexaroteneRetinoid X ReceptorsTetrahydronaphthalenes

Identifiers

PMID22927238
PMCPMC3479356
OpenAlexW2171026805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.